Erasca, Inc. company information, Employees & Contact Information

Precision Oncology Company Erasca to Share RAS/MAPK Cancer Therapy Updates at Morgan Stanley Conference Stock Titan

Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS) Seeking Alpha

Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Erasca enters another era, seeks partner for phase 3 ex-Novartis asset Fierce Biotech

Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway Nasdaq

Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds? Yahoo Finance

Erasca to Present at the Bank of America Securities Health Care Conference Stock Titan

Erasca Inc. (ERAS) reports earnings qz.com

Erasca’s pan-KRAS inhibitor ERAS-4001 gains IND clearance BioWorld MedTech

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans simplywall.st

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors ACS Publications

Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts Seeking Alpha

MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers MD Anderson Cancer Center

Erasca trims workforce and pipeline to focus on KRAS and molecular glues Pharmaceutical Technology

Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma Clinical Trials Arena

Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) Seeking Alpha

Erasca heads for phase 3 at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Stifel Initiates Coverage of Erasca (ERAS) with Buy Recommendation Nasdaq

Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options Fierce Biotech

Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) Seeking Alpha

Erasca Expands Leadership Team with Key Appointments citybiz

Erasca restructures; Novartis moves to complete MorphoSys deal BioPharma Dive

Watkins Advises Erasca on License Agreement With Novartis and Concurrent Common Stock Offering Latham & Watkins LLP

BofA Securities downgrades Erasca stock to Underperform on competitive concerns Investing.com

Stifel initiates coverage on Erasca stock with Buy rating, $4 price target Investing.com

Erasca and Pfizer enter trial partnership for palbociclib Clinical Trials Arena

Erasca Reports Progress and Financial Stability in Q2 2025 TipRanks

Erasca, Inc. Reports Strong Progress in Oncology Pipeline TipRanks

Erasca Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer PR Newswire

FDA Fast Tracks Naporafenib for Unresectable, Metastatic Melanoma Applied Clinical Trials

Novartis hands steering wheel to Erasca for melanoma med in $20M licensing deal Fierce Biotech

Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors Insider Monkey

Erasca buys-in assets from two China biotechs, slashes workforce BioWorld MedTech

Erasca collaborates with Novartis on cancer therapy trials Clinical Trials Arena

Erasca (ERAS) Zacks Investment Research

Will Erasca Inc. stock benefit from upcoming earnings reports - Earnings Overview Summary & Weekly Stock Breakout Alerts Trung tâm Dự báo KTTV quốc gia

Promising Penny Stocks To Consider In August 2025 simplywall.st

Why retail investors favor Erasca Inc. stock - July 2025 Pullbacks & Low Risk Entry Point Tips Trung tâm Dự báo KTTV quốc gia

Erasca patents new GTPase KRAS mutant degradation inducers BioWorld MedTech

Will Erasca Inc. stock benefit from upcoming earnings reports - 2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations Trung tâm Dự báo KTTV quốc gia

Portfolio Update: Will Erasca Inc. stock maintain growth story - July 2025 Rallies & Smart Allocation Stock Reports Fundação Cultural do Pará

Erasca picks up $42M to target biological drivers of cancer Fierce Biotech

Erasca files $500M mixed securities shelf MSN

Erasca discovers new KRAS inhibitors for cancer BioWorld MedTech

Preclinical activity described for Erasca's blood-brain barrier-penetrant EGFR inhibitor for glioblastoma BioWorld MedTech

Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline Citeline News & Insights

NiKang's new CFO appointment pays off with $200M fund raise from her previous employer Fierce Biotech

Erasca (ERAS) Stock Has Potential, Good Bet for High-Risk Investors Market Realist

Wall Street Zen Upgrades Erasca (NASDAQ:ERAS) to Hold Defense World